Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionOral CYP17 inhibitor
Molecular Target Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today